Free Trial

Enliven Therapeutics (ELVN) Insider Trading & Ownership

Enliven Therapeutics logo
$22.66 -0.68 (-2.91%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$22.68 +0.02 (+0.09%)
As of 07/18/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics (NASDAQ:ELVN) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
25.90%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
6
Amount Of
Insider Selling
(Last 12 Months)
$9.03M
Get ELVN Insider Trade Alerts

Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ELVN Insider Buying and Selling by Quarter

Enliven Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/10/2025Benjamin HohlCFOSell1,000$22.66$22,660.00  
7/7/2025Anish PatelCOOSell6,667$19.79$131,939.93  
6/27/2025Benjamin HohlCFOSell3,250$20.91$67,957.50  
6/20/2025Joseph P LyssikatosInsiderSell12,500$21.40$267,500.00  
6/17/2025Samuel KintzCEOSell12,500$22.18$277,250.00  
6/9/2025Anish PatelCOOSell6,667$20.34$135,606.78  
6/3/2025Joseph P LyssikatosInsiderSell7,500$20.03$150,225.00  
6/3/2025Samuel KintzCEOSell7,500$20.05$150,375.00  
5/27/2025Benjamin HohlCFOSell3,250$16.18$52,585.00  
5/19/2025Joseph P LyssikatosInsiderSell5,000$16.31$81,550.00  
5/19/2025Samuel KintzCEOSell5,000$16.49$82,450.00  
5/7/2025Anish PatelCOOSell6,667$18.39$122,606.13  
5/1/2025Joseph P LyssikatosInsiderSell5,030$20.07$100,952.10  
5/1/2025Samuel KintzCEOSell5,330$20.08$107,026.40  
4/28/2025Benjamin HohlCFOSell3,250$18.69$60,742.50  
4/21/2025Joseph P LyssikatosInsiderSell5,000$16.07$80,350.00  
4/17/2025Samuel KintzCEOSell5,000$16.42$82,100.00  
4/7/2025Anish PatelCOOSell6,667$18.04$120,272.68  
3/27/2025Benjamin HohlCFOSell3,250$21.33$69,322.50  
3/24/2025Benjamin HohlCFOSell1,000$22.50$22,500.00  
3/19/2025Joseph P LyssikatosInsiderSell12,500$20.61$257,625.00  
3/17/2025Samuel KintzCEOSell12,500$20.83$260,375.00  
3/7/2025Anish PatelCOOSell6,667$21.44$142,940.48  
2/27/2025Benjamin HohlCFOSell3,250$20.41$66,332.50  
2/7/2025Anish PatelCOOSell6,667$21.93$146,207.31  
2/5/2025Benjamin HohlCFOSell1,000$22.52$22,520.00  
1/27/2025Benjamin HohlCFOSell3,250$21.59$70,167.50  
1/7/2025Anish PatelCOOSell21,700$24.18$524,706.00  
1/3/2025Benjamin HohlCFOSell1,000$25.04$25,040.00  
12/30/2024Benjamin HohlCFOSell900$22.51$20,259.00  
12/27/2024Benjamin HohlCFOSell3,350$22.15$74,202.50  
11/27/2024Benjamin HohlCFOSell5,250$24.89$130,672.50  
10/28/2024Benjamin HohlCFOSell6,250$28.56$178,500.00  
10/18/2024Anish PatelCOOSell716$30.00$21,480.00  
10/18/2024Benjamin HohlCFOSell814$30.00$24,420.00  
10/18/2024Joseph P LyssikatosInsiderSell847$30.00$25,410.00  
10/18/2024Richard A HeymanDirectorSell817$30.00$24,510.00  
10/18/2024Samuel KintzCEOSell924$30.00$27,720.00  
10/15/2024Richard A HeymanDirectorSell1,270$27.67$35,140.90  
10/9/2024Joseph P LyssikatosInsiderSell37,878$28.16$1,066,644.48  
Altucher: Trump’s Great Gain is starting (Ad)

New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.

See Altucher’s Trump crypto prediction here
10/9/2024Samuel KintzCEOSell16,710$28.15$470,386.50  
10/8/2024Rahul D BallalDirectorSell10,420$28.17$293,531.40  
10/7/2024Benjamin HohlCFOSell1,270$27.51$34,937.70  
10/7/2024Joseph P LyssikatosInsiderSell2,707$27.61$74,740.27  
10/7/2024Samuel KintzCEOSell2,730$27.50$75,075.00  
10/4/2024Benjamin HohlCFOSell10,218$27.51$281,097.18  
10/4/2024Joseph P LyssikatosInsiderSell7,522$27.51$206,930.22  
10/4/2024Richard A HeymanDirectorSell2,825$27.51$77,715.75  
10/4/2024Samuel KintzCEOSell12,206$27.51$335,787.06  
10/1/2024Joseph P LyssikatosInsiderSell527$27.54$14,513.58  
10/1/2024Richard A HeymanDirectorSell518$27.54$14,265.72  
10/1/2024Samuel KintzCEOSell526$27.54$14,486.04  
9/30/2024Benjamin HohlCFOSell2,000$25.33$50,660.00  
9/27/2024Benjamin HohlCFOSell4,250$24.27$103,147.50  
8/29/2024Joseph P LyssikatosInsiderSell12,000$22.49$269,880.00  
8/27/2024Benjamin HohlCFOSell4,250$22.54$95,795.00  
8/26/2024Samuel KintzCEOSell12,000$22.89$274,680.00  
8/15/2024Richard A HeymanDirectorSell1,270$23.25$29,527.50  
7/31/2024Benjamin HohlCFOSell991$27.53$27,282.23  
7/31/2024Joseph P LyssikatosInsiderSell3,099$27.56$85,408.44  
7/31/2024Richard A HeymanDirectorSell1,702$27.51$46,822.02  
7/31/2024Samuel KintzCEOSell2,270$27.56$62,561.20  
7/29/2024Benjamin HohlCFOSell5,250$26.68$140,070.00  
7/29/2024Joseph P LyssikatosInsiderSell12,000$26.70$320,400.00  
7/25/2024Samuel KintzCEOSell12,000$24.92$299,040.00  
(Data available from 1/1/2013 forward)

ELVN Insider Trading Activity - Frequently Asked Questions

The list of insiders at Enliven Therapeutics includes 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta, and Samuel Kintz. Learn more on insiders at ELVN.

25.90% of Enliven Therapeutics stock is owned by insiders. Learn more on ELVN's insider holdings.

The following insiders have sold ELVN shares in the last 24 months: 5Am Partners Vi, Llc ($17,502,500.00), Anish Patel ($3,661,205.55), Benjamin Hohl ($2,657,959.54), Joseph P Lyssikatos ($3,002,129.09), Rahul D Ballal ($1,700,961.11), Richard A Heyman ($349,650.29), Rishi Gupta ($22,877,262.00), and Samuel Kintz ($5,507,974.18).

Insiders have sold a total of 3,027,754 Enliven Therapeutics shares in the last 24 months for a total of $59,114,403.44 sold.

Enliven Therapeutics Key Executives

  • Mr. Samuel S. Kintz M.B.A. (Age 38)
    Co-Founder, CEO, Secretary & Director
    Compensation: $866.41k
  • Dr. Joseph P. Lyssikatos Ph.D. (Age 59)
    Co-Founder & Chief Scientific Officer
    Compensation: $632.67k
  • Dr. Helen Louise Collins M.D. (Age 61)
    Chief Medical Officer
    Compensation: $686.19k
  • Mr. Anish Patel Pharm.D. (Age 43)
    Co-Founder & COO
  • Mr. Benjamin  HohlMr. Benjamin Hohl (Age 34)
    CFO & Head of Corporate Development
    Compensation: $488.5k
    9 recent trades
  • Dr. Galya D. Blachman Esq. (Age 47)
    Ph.D., Chief Legal Officer & Head of Business Development


This page (NASDAQ:ELVN) was last updated on 7/20/2025 by MarketBeat.com Staff
From Our Partners